Hitchhiking cancer vaccine makes progress in the clinic
Elicio Therapeutics is testing a pancreatic cancer vaccine using technology first developed at MIT in clinical trials, with promising Phase 1 results.
Stay updated with breaking news from Darrell Irvine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Elicio Therapeutics is testing a pancreatic cancer vaccine using technology first developed at MIT in clinical trials, with promising Phase 1 results.
Vaccines that target tumors with specific genetic mutations in pancreatic and other cancers have shown promise in early-stage trials
Using a virus-like delivery particle made from DNA, researchers from MIT and the Ragon Institute of MGH, MIT, and Harvard have created a vaccine that can induce a strong antibody response against SARS-CoV-2.
<p>Using a DNA-based delivery particle, researchers created a vaccine that can induce a strong antibody response against SARS-CoV-2.</p>
MIT and Ragon Institute create SARS-CoV-2 vaccine using DNA particles for effective antibody response.